Internal link ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP June 26, 2025 at 08:30 PM UTC
Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences May 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results May 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference May 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 May 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth April 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results March 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration December 11, 2024 at 12:00 PM UTC
Internal link ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist December 10, 2024 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 December 05, 2024 at 01:00 PM UTC
Internal link ProQR Announces Third Quarter 2024 Operating and Financial Results November 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement October 25, 2024 at 08:45 PM UTC
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement October 23, 2024 at 02:15 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares October 22, 2024 at 08:01 PM UTC
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society October 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference September 10, 2024 at 08:30 PM UTC
Internal link ProQR Announces Second Quarter 2024 Operating and Financial Results August 08, 2024 at 11:00 AM UTC
Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit June 18, 2024 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2024 Operating and Financial Results May 09, 2024 at 11:00 AM UTC
Internal link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases May 08, 2024 at 12:00 PM UTC
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 April 23, 2024 at 11:00 AM UTC
Internal link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting April 22, 2024 at 08:31 PM UTC
Internal link ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio April 19, 2024 at 11:00 AM UTC
Internal link ProQR Announces Year End 2023 Operating and Financial Results March 13, 2024 at 11:00 AM UTC
Internal link ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing February 15, 2024 at 12:00 PM UTC